Audentes specializes in gene therapy drugs to treat rare diseases.
The goal of the acquisition is to allow Astellas to address “unmet needs of patients living with serious, rare diseases,” Astellas President and CEO Kenji Yasukawa said.
By acquiring Audentes, Astellas is adding gene therapy as one of the company’s primary focuses, a news release from the company said.
The deal is expected to close in the first quarter of 2020.
Read the full news release here.
More articles on pharmacy:
Top 5 pharmacy stories in November
Juno Therapeutics co-founder starting new drug company
Parents in Europe crowdsource $2.7M to buy world’s most expensive drug for their toddler
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.